Difference between revisions of "Work Product for Review"
Jump to navigation
Jump to search
Line 1: | Line 1: | ||
− | + | QIBA documents are posted for [[Public Comment Process|Public Comment]] to ensure stakeholder representation, transparency and quality review. Interested people are encouraged to provide input on the document, the scenarios and use cases they address, the technologies proposed and other details. | |
− | QIBA documents are posted for Public Comment to ensure stakeholder representation, transparency and quality review. Interested people are encouraged to provide input on the document, the scenarios and use cases they address, the technologies proposed and other details | ||
− | |||
− | |||
==Comment Submission== | ==Comment Submission== | ||
Line 10: | Line 7: | ||
:* Provide your name or initials | :* Provide your name or initials | ||
:* Follow the other instructions on the page | :* Follow the other instructions on the page | ||
+ | :* CLICK SUBMIT | ||
* e-mail ([mailto:sweinmann@rsna.org Susan Weinmann]) with ''general comments'' about the Profile/Protocol concept, structure, process, etc. | * e-mail ([mailto:sweinmann@rsna.org Susan Weinmann]) with ''general comments'' about the Profile/Protocol concept, structure, process, etc. | ||
+ | The [[Committees|QIBA Biomarker Committees]] consider all comments submitted, and where appropriate, post responses. | ||
− | == | + | ==Public Comment Documents== |
− | + | ''Public Comment closes March 1, 2017'' | |
− | *[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | QIBA Profile: | + | *[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | QIBA Profile: <font color=red>Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016</font>]] |
− | + | *[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|QIBA Profile Checklist: <font color=red>SPECT Profile Conformance</font>]] | |
− | *[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|QIBA SPECT Profile Conformance | ||
− | |||
− | *[[Media:QIBA_CT_Vol_LungNoduleAssessmentInCTScreening_v5-2-16b.docx|QIBA Profile: | + | ''Public Comment closed'' |
+ | *[[Media:QIBA_CT_Vol_LungNoduleAssessmentInCTScreening_v5-2-16b.docx|QIBA Profile: <font color=red> QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening, June 1, 2016</font>]] | ||
− | *[[Media:QIBA Small Nodule Profile References - Accuracy.xlsx|QIBA Spreadsheet: | + | *[[Media:QIBA Small Nodule Profile References - Accuracy.xlsx|QIBA Spreadsheet: <font color=red> Small Nodule Profile References_Accuracy. Version for Public Comment. June 1, 2016 </font>]] |
− | *[[Media:QIBA Small Nodule Profile References - Precision.xlsx|QIBA Spreadsheet: | + | *[[Media:QIBA Small Nodule Profile References - Precision.xlsx|QIBA Spreadsheet: <font color=red> Small Nodule Profile References_Precision. Version for Public Comment. June 1, 2016 </font>]] |
*[[Document Archive]] | *[[Document Archive]] |
Revision as of 22:11, 9 February 2017
QIBA documents are posted for Public Comment to ensure stakeholder representation, transparency and quality review. Interested people are encouraged to provide input on the document, the scenarios and use cases they address, the technologies proposed and other details.
Comment Submission
- Visit the QIBA Public Comment Webform.
- Select the document you are commenting on from the dropdown menu
- Provide your name or initials
- Follow the other instructions on the page
- CLICK SUBMIT
- e-mail (Susan Weinmann) with general comments about the Profile/Protocol concept, structure, process, etc.
The QIBA Biomarker Committees consider all comments submitted, and where appropriate, post responses.
Public Comment Documents
Public Comment closes March 1, 2017
- QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016
- QIBA Profile Checklist: SPECT Profile Conformance
Public Comment closed
- QIBA Spreadsheet: Small Nodule Profile References_Accuracy. Version for Public Comment. June 1, 2016